To further validate the protective effect of ranolazine on the CNS, we quantified the protein levels of GFAP, a marker of astrocytes activation, whose levels are dysregulated in AD [22,23], and mRNA expression of the master regulator of inflammation, TNF-α, in biopsies [20] of brain tissue. Here, GFAP is linked to Alzheimer disease.